HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Pediculicide Amendment Permits Detailed Insert Instructions

This article was originally published in The Tan Sheet

Executive Summary

Detailed use instructions for pediculicide products under the heading "Other information" may appear in a package insert, FDA states in a final amendment to the Pediculicide OTC Final Monograph, published in the Federal Register Dec. 31

You may also be interested in...



Pediculicide Detailed Use Instructions Belong On Package Insert – CHPA

Lengthy, detailed directions on environmental control of lice and combing to remove nits from hair need not be included on the outer label of OTC pediculicides, the Consumer Healthcare Products Association says

Pyrethrum Pediculicide Labeling Revisions Would Provide More Detail – FDA

FDA's proposed amendment of the pediculicide drug products final monograph would appear to bring labeling for such drugs in line with that of OTC lice treatments approved under an NDA

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

RS127700

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel